Related Experiment Video
Updated: Jul 18, 2025
Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
Published on: May 23, 2021
Unveiling the Culprit: Candida-Induced Spondylodiscitis Following SARS-CoV-2 Infection
Mohammad O Khalil1, Laith A Ayasa2, Anas Odeh3
1Faculty of Medicine, Al-Quds University, Jerusalem, PSE.
Abstract:
We present a case of a 57-year-old male patient with a history of prolonged intensive care unit (ICU) stay for coronavirus disease 2019 (COVID-19) who developed fungal spondylodiscitis, a rare complication. The patient initially presented complaining of respiratory symptoms and was subsequently treated with tocilizumab, remdesivir, enoxaparin, and dexamethasone. Following ICU discharge, he experienced recurrent infections, including extended-spectrum beta-lactamase Klebsiella urinary tract infection. Two months later, he developed back pain; magnetic resonance imaging (MRI) revealed inflammatory spondylodiscitis. Despite empirical antibiotic therapy, his condition did not improve, and a bone biopsy confirmed Candida albicans infection. Antifungal treatment with fluconazole and anidulafungin resulted in a significant clinical improvement. The patient achieved complete recovery after six months of therapy. This case highlights the rare occurrence of fungal spondylodiscitis in COVID-19 patients with a history of ICU stay and emphasizes the importance of early recognition and appropriate management to mitigate potential complications.
Insights
A rare fungal infection, Candida albicans spondylodiscitis, developed in a COVID-19 patient after prolonged intensive care unit (ICU) stay. Prompt antifungal treatment led to full recovery, highlighting the need for vigilance in post-ICU care.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Mycology
Background:
- Coronavirus disease 2019 (COVID-19) can lead to prolonged intensive care unit (ICU) stays.
- Patients with severe COVID-19 may experience secondary infections due to immune dysregulation and invasive procedures.
- Fungal infections, though less common than bacterial infections, pose a significant risk in immunocompromised patients.
Observation:
- A 57-year-old male with a history of prolonged ICU stay for COVID-19 developed recurrent infections.
- Following treatment for extended-spectrum beta-lactamase Klebsiella urinary tract infection, the patient presented with back pain.
- Magnetic resonance imaging (MRI) revealed inflammatory spondylodiscitis, and bone biopsy confirmed Candida albicans infection.
Findings:
- Empirical antibiotic therapy was ineffective for the patient's spondylodiscitis.
- Diagnosis of Candida albicans spondylodiscitis was confirmed via bone biopsy.
- Antifungal treatment with fluconazole and anidulafungin resulted in significant clinical improvement.
Implications:
- This case underscores the rare but serious complication of fungal spondylodiscitis in post-ICU COVID-19 patients.
- Early recognition and targeted antifungal therapy are crucial for managing invasive fungal infections in this population.
- Highlights the importance of considering fungal etiologies in persistent infections following severe COVID-19 and prolonged ICU stays.
